MedTrace Logo

Treatment of Major Depressive Disorder in the UK Using TMS Therapy

NCT04217837 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2021-10-08

No results posted yet for this study

Summary

The major objective of this observational study is to describe clinical outcomes of patients in the UK receiving treatment with the NeuroStar TMS Therapy system in routine clinical practice.

Conditions

Interventions

DEVICE

Transcranial Magnetic Stimulator

Transcranial magnetic stimulation (TMS) uses a targeted pulsed magnetic field, similar to what is used in an MRI (magnetic resonance imaging) machine. While the patient is awake and alert, NeuroStar TMS Therapy stimulates areas of the brain that are underactive in depression.

Sponsors & Collaborators

  • Neuronetics

    lead OTHER

Principal Investigators

  • Mohamed Abdelghani, MBBCh, MSc, MRCPsych · St. Pancras Hospital

Eligibility

Min Age
22 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-31
Primary Completion
2022-02-28
Completion
2022-02-28
FDA Device
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04217837 on ClinicalTrials.gov